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Comparative effectiveness of carotid arterial
stenting versus endarterectomy
Peter W. Groeneveld, MD, MS,a,b,c Lin Yang, MS,b Alexis Greenhut, MPH,b and
Feifei Yang, MS,b Philadelphia, Pa
Background: Carotid arterial stent (CAS) systems are an alterative to carotid endarterectomy for the treatment of
moderate to severe carotid stenosis, but the effectiveness of CAS compared to endarterectomy in preventing stroke and
death is uncertain. This study’s objective was to compare the clinical outcomes among Medicare beneficiaries undergoing
carotid revascularization before and after CAS became widely available.
Objectives: This observational, retrospective cohort study compared 46,784 patients undergoing carotid revascularization
from August 2005-March 2006 (the coverage era) to propensity-score-matched patients undergoing carotid revascular-
ization between October 2002-September 2004 (the pre-coverage era), before widespread Medicare coverage of CAS.
Methods: Mortality was compared at 90 and 270 days after revascularization, as were the combined outcomes of
periprocedural acute myocardial infarction and any stroke or death within 90 and 270 days after revascularization,
between the two eras. Comparisons were also made between localities with high (23% of carotid procedures being CAS)
and lower (9% of carotid procedures being CAS) adoption rates of carotid stents during the coverage era.
Results: There were no significant differences in 90-day mortality (2.2% vs 2.2%; P  .79), 90-day combined outcomes
(4.5% vs 4.3%; P  .13), or 270-day mortality (4.8% vs 4.6%; P  .17) between the coverage and pre-coverage eras, but
there were more 270-day combined outcomes in the coverage era (7.7% vs 7.3%; P  .03). In localities with higher
adoption of carotid stents, there was higher 90-day mortality (adjusted odds ratio [OR] 1.15; P .16), 90-day combined
outcomes (OR 1.17; P .03), 270-day mortality (OR 1.13; P .07), and 270-day combined outcomes (OR 1.10;
P  .09) in the coverage era. There were no differences in event rates between eras in areas with lower carotid stent
adoption.
Conclusion: The adoption of carotid stents for treatment of carotid stenosis was associated with increased rates of adverse
clinical outcomes after carotid revascularization. (J Vasc Surg 2009;50:1040-8.)Carotid endarterectomy (CEA) reduces the incidence
of stroke and death among patients with symptomatic
carotid arterial stenosis,1,2 yet the perioperative complica-
tion rate is not insignificant,3 and the American Academy of
Neurology recommends that endarterectomy be avoided in
patients with 6% risk of perioperative complications or
with an expected survival of 5 years.4 Carotid arterial
stenting (CAS) with cerebral protection was approved by
the Food and Drug Administration (FDA) in 2004 as an
alternative therapy to endarterectomy among patients at
high risk for perioperative complications.5 Clinical trials
comparing CAS to CEA have yielded conflicting re-
sults.6-11 Two ongoing large multicenter randomized
controlled trials comparing endarterectomy to CAS—
the Carotid Revascularization Endarterectomy vs Stent-
ing Trial (CREST) and the International Carotid Stent-
ing Study (ICSS)—are completing enrollment and may
further establish whether CAS efficacy is comparable to
endarterectomy.12,13
From the Department of Medicine, Philadelphia Veterans Affairs Medical
Center,a Division of General Internal Medicine, University of Pennsylva-
nia School of Medicine,b Leonard Davis Institute of Health Economics,
University of Pennsylvania.c
Competition of interest: none.
Reprint requests: Peter W. Groeneveld, MD, MS, 1229 Blockley Hall, 423
Guardian Drive, Philadelphia, PA 19104-6021 (e-mail: peter.groeneveld@
va.gov).
0741-5214/$36.00
Published by Elsevier Inc. on behalf of the Society for Vascular Surgery.
doi:10.1016/j.jvs.2009.05.054
1040Nevertheless, it remains uncertain how CAS performs
in comparison to CEA outside the context of clinical trials.
Prior investigations of carotid revascularization procedures
among the Medicare population have revealed important
differences in the clinical outcomes achieved by hospitals
that were involved in the clinical trials compared to hospi-
tals that did not participate in clinical trials.14 Recognizing
the variability in a hospital’s ability to deliver optimal
outcomes from carotid revascularization, the Centers for
Medicare and Medicaid Services (CMS) reimburses CAS
only for hospitals that meet qualifying requirements (eg,
prior procedural experience, appropriate ancillary services,
adequate case volume, etc).15 It is uncertain whether this
coverage policy resulted in comparable CEA and CAS
clinical outcomes.
The goal of our research was to compare the effective-
ness of CAS to CEA in a nonexperimental, nationwide
population of Medicare beneficiaries receiving carotid re-
vascularization after the March 2005 Medicare coverage
expansion for CAS.
METHODS
Observational studies comparing CEA to CAS are
complicated by the strong selection effects inherent in the
nonrandomized assignment of patients to therapy. Direct
comparisons between CEA and CAS recipients are likely to
be confounded by factors that are unobservable, even with
highly detailed clinical databases. To surmount this diffi-
culty, we assessed the aggregate clinical outcomes of pa-
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regions. From 2005-2006, the percentage of all carotid
revascularizations that were CAS varied across localities
from 0-25%. Had there been differences in the effective-
ness of CEA vs CAS, there should have likewise been
differences in clinical outcomes among carotid proce-
dure patients across regions, with adverse event rates
correlated with CAS adoption. A similar approach has
been used in other studies utilizing observational data.11
To control for the possibility that high-CAS utilization
areas were systematically different from low-CAS utiliza-
tion areas in health care quality or patient characteristics, we
compared outcomes within localities between two distinct
eras (ie, the era immediately before Medicare coverage of
CAS, and the era subsequent to widerMedicare coverage of
CAS—Fig 1), to control for time-invariant differences in
carotid procedural outcomes across regions. This analytic
technique of comparing the temporal differences in out-
comes within fixed spatial units is known as “difference-in-
difference” estimation.16
Selection and exclusion criteria. We examined fee-
for-service Medicare claims for patients receiving either
CEA or CAS during two “eras.” The “pre-coverage” era
was defined as October 1, 2002, through September 30,
2004, when CAS was only covered for Medicare beneficia-
ries enrolled in clinical trials. The “coverage era” was de-
fined as August 1, 2005, throughMarch 31, 2006, after the
CMS implemented a national coverage decision expanding
eligibility for CAS (March 17, 2005). Carotid stent utiliza-
tion was determined by International Classification of Dis-
Fig 1. Growth in carotid arterial stent utilization amon
number of carotid arterial stent (CAS) procedures perf
“pre-coverage era.” The dark gray background indicate
widespread Medicare coverage of CAS was implementedeases, 9th revision procedure codes 00.55 or 39.90 (beforeOctober 1, 2004) or codes 0.061 and 0.063 (starting on
October 1, 2004) with concurrent diagnosis codes 433.10,
433.11, 433.30, or 433.31. Endarterectomy was deter-
mined by procedure code 38.12. We included only patients
who were older than age 66 to provide at least 1 year of
prior claims for each patient. We excluded patients who
received carotid revascularization outside of the 50 states or
the District of Columbia, or who had received prior carotid
revascularization within 12 months. Due to coding limita-
edicare beneficiaries, 2002-2006. The bars indicate the
d per month. The light gray background indicates the
“coverage era.” The black arrow indicates the date that
Fig 2. Geographic differences in carotid arterial stent utilization,
2005-2006. The 306 U.S. hospital referral regions are shaded
based on the relative utilization rates of carotid arterial stent
(CAS). The top 20% of hospital referral regions for CAS use are
shaded in black, with progressively lighter gray colors indicating
progressively lower quintiles of CAS use, with white indicating the
lowest CAS-utilization quintile.g M
orme
s thetions, we could not assess whether patients had symptom-
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could we assess medication use.
Demographic information was obtained from Medi-
care’s enrollment database. Clinical comorbidities among
carotid revascularization patients were determined by ex-
amining diagnosis codes included in the claim in which the
carotid procedure was performed, and all other inpatient
and outpatient claims in the 12 months preceding the
carotid procedure. Information about the hospital per-
forming the carotid procedure was obtained fromMedicare
Hospital Cost Report Information System annual reports.
Members of the American Association ofMedical College’s
Council of Teaching Hospitals and Health Systems were
designated as academic hospitals. Hospitals located in met-
ropolitan statistical areas with 1 million inhabitants were
designated as urban hospitals.17
Hospital referral regions. We selected the Dart-
mouth Atlas for Healthcare’s Hospital Referral Region
Table I. Characteristics of pre-coverage era and coverage
propensity score matchinga
Characteristic Pre-
Carotid stent recipients
Logit of propensity score (sd)
Age, mean (sd)
Female
Race
White
Black
Other
Cardiovascular disease
Hypertension
Coronary artery disease
Peripheral vascular disease
Valvular heart disease
Congestive heart failure
Prior transient ischemic attack
Prior stroke
Clinical co-morbidity
Diabetes
Chronic pulmonary disease
Cancer (no metastasis)
Hypothyroidism
Renal disease
Hospitalization in 1-year before carotid procedure
Characteristics of hospital performing carotid procedure
Urban hospitald
Academic hospitale
5,000 admissionsf per year
5,000-9,999 admissionsf per year
10,000 admissionsf per year
HRR, Hospital referral region; CAS, carotid arterial stent; SD, standardized
aAll values given as n, (%) unless otherwise indicated. Percentages may not
bStandardized difference: the difference in means as a percentage of the poo
c23% of pre-coverage era patients matched to more than one coverage era p
dHospital located in an urban county (U.S. Department of Agriculture defi
eHospital was a member of the American Association of Medical College’s
fAverage Medicare admissions per calendar year, 2004-2005.(HRR) as the geographic unit of analysis, as the availabilityof CAS in 2005-2006 varied markedly across HRRs.18
These 306 contiguous geographic units were originally
defined as localities within which Medicare beneficiaries
receive the vast majority of their hospital care.We examined
the ratio of CAS procedures to all carotid revascularization
(CAS  CEA) procedures among patients in each HRR in
both the pre-coverage and coverage eras. We calculated the
percentage point increase in CAS use in eachHRR between
eras as a measure of the extent of CAS adoption in each
locality. HRRs were divided into quintiles of HRR adop-
tion rates during the coverage era.
Propensity score match. To further decrease the bias
introduced by comparing outcomes among carotid revas-
cularization recipients between eras, we used propensity
scores19,20 to match carotid revascularization recipients
within HRRs across eras. Matching patients within HRRs
assured balance of time-invariant HRR-level factors across
comparison groups. We thus fitted logistic regression mod-
arotid revascularization patients before and after
Before match (all HRRs)
age era (n  138,885) Coverage era (n  47,386) SDb
4590 (3.3) 5354 (11) N/A
1.24 (1.31) 0.96 (0.52) 27.9
76 (6) 76 (6) 1.4
78,736 (57) 27,160 (57) 1.3
30,865 (94) 44,460 (94) 1.7
4,216 (3) 1,607 (3) 2.0
3,804 (3) 1,319 (3) 0.3
94,045 (68) 32,474 (69) 1.8
59,478 (43) 21,007 (44) 3.0
21,078 (15) 7562 (16) 2.2
9138 (7) 3844 (8) 5.9
9184 (7) 3684 (8) 4.5
3756 (3) 1216 (3) 0.9
1012 (0.7) 719 (1.5) 7.5
34,031 (25) 11,958 (25) 1.7
25,364 (18) 9603 (20) 5.1
12,185 (9) 4204 (9) 0.3
11,420 (8) 4081 (9) 1.4
2290 (2) 2402 (5) 19.1
39,812 (92) 68,129 (92) 0.6
59,667 (43) 20,415 (43) 0.2
28,377 (20) 9842 (21) 0.8
44,462 (32) 15,013 (32) 0.7
62,089 (45) 21,431 (45) 1.0
32,334 (23) 10,942 (23) 0.5
rence; sd, standard deviation.
100 due to rounding.
andard deviation.
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hauser method),21 and hospital characteristics (academic
center, urban location, cardiovascular volume) as indepen-
dent variables. We then matched pre-coverage and cover-
age era patients within each HRR, using the closest Mahal-
anobis match within propensity score calipers, permitting
pre-coverage era patients to control for more than one
coverage era patient.19,20 In our primary analysis, we pur-
posefully did not match patients based on their actual receipt
of CAS vs CEA to avoid introducing the confounding-by-
indication bias described above.
Outcomes analysis. Clinical outcomes were assessed
using Medicare claims in the 270 days after procedure
receipt. Medicare’s “Denominator” file was used to assess
mortality—death records are cross-linked to the Social
Security Death Master File, and a high level of accuracy in
mortality reporting has been confirmed. The occurrence of
acute myocardial infarction (AMI) was determined by the
Table I. Continued.
Aft
Top 20% HRRs: CAS adoption
Pre-coverage era (n  9044c) Coverage era (n  9044) SDb
424 (4.7) 2051 (23) N/A
0.93 (0.57) 0.91 (0.60) 4.3
76 (6) 76 (6) 2.5
3807 (42) 3809 (43) 3.8
8,473 (94) 8,370 (93) 2.2
320 (3) 390 (4) 1.1
251 (3) 284 (3) 1.9
6246 (69) 6131 (68) 1.1
4229 (47) 4192 (46) 1.0
1390 (15) 1477 (16) 3.1
655 (7) 707 (8) 2.4
713 (8) 732 (8) 2.9
233 (3) 251 (3) 0.8
92 (1.0) 113 (1.2) 1.8
2320 (26) 2313 (26) 0.3
1775 (20) 1871 (21) 2.7
702 (8) 751 (8) 2.9
681 (8) 794 (9) 4.0
334 (4) 369 (4) 2.0
8,499 (94) 8,480 (94) 3.6
4660 (52) 4684 (52) 0.5
1594 (18) 1632 (18) 0.4
2995 (33) 2990 (33) 0.9
4597 (51) 4613 (51) 1.0
1452 (16) 1441 (16) 0.3appearance of diagnosis code 410.xx, and the occurrence ofstroke was determined by the appearance of diagnosis codes
433.01, 433.11, 433.21, 433.31, 433.81, 433.91, 434.01,
434.11, 434.91, or 436. After a formula for combining
clinical outcomes often used in carotid revascularization
clinical trials,6 we combined outcomes of any stroke (claims
do not indicate laterality, thus we included all strokes rather
than ipsilateral stroke) or death after the revascularization
procedure, or any AMI within 30 days of the procedure.6
We calculated 90-day and 270-day mortality and combined
adverse outcomes across quintiles of CAS adoption rates.
We then estimated a logistic regression model, using gen-
eralized estimating equations to account for matched ob-
servations, with 90-day mortality as the dependent variable
and propensity score, treatment in the coverage era, treat-
ment in a high-CAS-adoption HRR, and the interaction
between coverage era and high-CAS-adoption HRR as
independent variables. We estimated similar logistic regres-
sion models for 90-day combined adverse events (death,
tch
Bottom 80% HRRs: CAS adoption
-coverage era (n  37,740c) Coverage era (n  37,740) SDb
1188 (3.1) 3225 (8.5) N/A
0.96 (0.55) 0.94 (0.58) 2.5
76 (6) 76 (6) 1.9
15,979 (42) 16,114 (43) 1.9
35,712 (95) 35,591 (94) 4.4
1,087 (3) 1,152 (3) 3.9
941 (2) 997 (3) 2.1
26,257 (70) 26,063 (69) 2.7
16,576 (44) 16,564 (44) 0.8
5679 (15) 5983 (16) 2.6
2803 (7) 3055 (8) 2.2
2596 (7) 2829 (8) 0.8
884 (2) 932 (3) 1.2
383 (1.0) 457 (1.2) 2.3
9428 (25) 9482 (25) 0.2
7183 (19) 7582 (20) 2.7
3242 (9) 3403 (9) 2.0
2959 (8) 3251 (9) 4.5
1586 (4) 1640 (4) 2.3
35,132 (93) 34,862 (92) 0.9
15,569 (41) 15,552 (41) 0.5
7974 (21) 8094 (21) 1.1
11,881 (31) 11,798 (31) 0.1
16,448 (44) 16,545 (44) 0.4
9411 (25) 9397 (25) 0.3er ma
Prestroke, or AMI), 270-day mortality, and 270-day com-
pre-c
otid p
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9.2 (Cary, NC) or STATA 10.1 (College Station, Tex).
RESULTS
AmongMedicare beneficiaries, CAS use nearly quadru-
pled between early 2004 (266 procedures/month) and late
2006 (1015 procedures/month; P  .001) while carotid
endarterectomy utilization dropped during the same peri-
ods from 7820 procedures/month to 6519 procedures/
month (P  .001). The overall number of carotid revascu-
larization procedures remained statistically unchanged
between October 2003 and March 2006 (average change
in procedures per month  17.6; P  .11 for trend).
Geographic utilization of CAS was highly variable (Fig 2).
We initially identified 138,885 pre-coverage-era and
47,386 coverage era carotid revascularization patients, with
the ratio reflective of the pre-coverage era being 24 months
compared to the 8-month coverage era. After implement-
ing the propensity score match, 46,784 coverage era
patients (99%) could be matched to 35,778 unique pre-
coverage-era patients (Table I), with 8359 pre-coverage-
era patients matching more than 1 coverage-era patient
(average number of matches per multiply-matched pre-
coverage patient  2.3). Comparisons of the standardized
difference (ie, difference inmeans divided by the pooled sd)
between matched groups indicated both patient and hos-
pital characteristics were highly similar.
Patient characteristics. Patients in the matched co-
horts were predominantly white and nearly 60% were men.
Few patients (4%) had a prior diagnosis of stroke or
Table II. Clinical outcomes among carotid revascularizati
hospital referral region adoption rates of CAS
HRR CAS adoption quintile 1 (highest)
N (both eras) 18,088 2
% CAS use in pre-coverage era 4.7
% CAS use in coverage era 22.7
90-day mortality, pre-coverage era 2.1
90-day mortality, coverage era 2.4
RRa (CI) 90-day mortality 1.08 (0.97-1.20) 1.09 (0
90-day AMIb/stroke/death
pre-coverage era 4.6
90-day AMIb/stroke/death
coverage era 5.2
RRa (CI) 90-day AMIb/stroke/
death 1.09 (1.01-1.18) 1.04 (0
270-day mortality, pre-coverage era 4.1
270-day mortality, coverage era 4.8
RRa (CI) 270-day mortality 1.07 (0.997-1.151) 1.04 (0
270-day AMIb/stroke/death
pre-coverage era 7.4
270-day AMIb/stroke/death
coverage era 8.1
RRa (CI) 270-day AMIb/stroke/
death 1.05 (0.995-1.112) 1.04 (0
HRR, Hospital referral region; CAS, carotid arterial stent; RR, risk ratio; C
aRelative risk for clinical outcome among coverage era patients compared to
bAMI counted as an event only when occurring within 30 days after the cartransient ischemic attack, although nearly half of thepatients had coronary artery disease, 25% had diabetes,
15-16% had non-carotid peripheral vascular disease, and
19-21% had chronic pulmonary disease. Approximately
40-50% of patients were treated at urban hospitals, and
18-21% of patients were treated at academic hospitals.
Rates of death and combined clinical outcomes.
Overall rates of death among pre-coverage and coverage-era
patients were comparable at both 90 days (pre-coverage:
2.2%; coverage: 2.2%; P  .79) and 270 days (pre-coverage:
4.6%; coverage: 4.8%; P  .17) subsequent to carotid revas-
cularization. Rates of combined outcomes (ie, early AMI, any
stroke/death) were similar in the two cohorts at 90 days
(pre-coverage: 4.3%; coverage: 4.5%; P  .13), but at 270
days there was a significantly higher rate of the combined
outcomes in the coverage era (pre-coverage: 7.3%; coverage:
7.7%; P .03).
Outcomes by geographic subgroup. We then calcu-
lated the CAS rate in each HRR during the pre-coverage
and coverage eras, and we divided the matched cohorts
across quintiles of HRR adoption rates for CAS. Utilization
rates of CAS across these five quintiles ranged from 1% in
the lowest quintile to 23% in the highest quintile (Table II).
There were no significant differences between unadjusted
rates of pre-coverage-era and coverage-era mortality or
combined adverse clinical outcomes in the lower four ter-
tiles for CAS adoption. In the highest tertile for CAS
adoption, there were higher rates of 90-day mortality (risk
ratio [RR]  1.08; P  .16), 270-day mortality (RR 
1.07; P  .06), 90-day combined outcomes (RR  1.09;
P  .03) and 270-day combined outcomes (RR  1.05;
atients in pre-coverage vs coverage era, by quintile of
3 4 5 (lowest)
24,662 14,770 11,114
.3 3.2 2.4 1.4
.3 8.6 4.5 0.8
.0 2.1 2.6 2.1
.4 1.9 2.3 1.9
-1.199) 0.94 (0.87-1.02) 0.95 (0.86-1.04) 0.93 (0.82-1.05)
.8 4.5 4.8 4.4
.1 4.4 4.7 4.4
1.10) 0.97 (0.92-1.04) 1.02 (0.95-1.11) 1.01 (0.92-1.11)
.5 4.2 4.5 3.9
.8 4.0 4.6 4.0
1.10) 0.99 (0.94-1.05) 0.99 (0.92-1.07) 1.01 (0.92-1.11)
.7 7.2 7.4 6.6
.2 7.2 7.6 6.9
1.09) 1.00 (0.96-1.05) 1.02 (0.96-1.09) 1.03 (0.95-1.11)
confidence interval.
overage era patients.
rocedure.on p
2
4,934
4
14
2
2
.999
4
5
.97-
4
4
.98-
7
8
.99-
I, 95%P  .09).
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separately fit logistic regression models predicting 90-day
and 270-day mortality, and the 90-day and 270-day com-
bined adverse outcomes. Each model contained a predictor
variable indicating the coverage era, a predictor indicating
whether the patient was in a high-CAS-adopting HRR (ie,
the top quintile of HRRs for CAS adoption), an interaction
term between these predictors, and covariates for which the
standardized difference in the matched cohorts exceeded
2%. We observed minimal differences between adjusted
pre-coverage-era and coverage-era outcomes among pa-
tients who were not in the highest CAS-adoption HRR
quintiles, with odds ratios ranging from 0.96 to 1.03 (all
P values  .33; Fig 3). Conversely, adjusted odds ratios
for adverse outcomes in the coverage era in the highest
CAS-adoption HRR quintile were higher, with the odds
ratio (95% confidence interval) for 90-day mortality 
1.15 (0.95 to 1.41; P  .15), 270-day mortality  1.13
(0.99 to 1.30; P  .07), 90-day combined adverse
outcome  1.17 (1.02 to 1.35; P  .03), and 270-day
combined adverse outcome  1.10 (0.98 to 1.23; P 
.09).
Qualitatively similar results were obtained when we
selected different quantiles (eg, quartiles, deciles, etc) for
dividing patients geographically. Our results also did not
substantially change when additional covariates were added
Fig 3. Adjusted odds ratios for clinical outcomes of carotid pro-
cedures comparing the rate of adverse outcomes in the carotid
arterial stent (CAS) coverage era to the rate of adverse outcomes in
the pre-coverage era, with odds ratios greater than 1 indicating
more frequent adverse outcomes during the CAS coverage era.
The “Top 20%” dots and error bars refer to the adjusted odds
ratios and 95% confidence intervals for clinical outcomes among
patients in the geographic areas with the highest adoption rates of
carotid arterial stents (ie, the top quintile). The “Lower 80%” dots
and error bars refer to the adjusted odds ratios and 95% confidence
intervals for clinical outcomes among patients located in geo-
graphic areas that were not in the top 20% for CAS adoption.
*Indicates combined clinical outcomes of any peri-procedural
myocardial infarction, any stroke, or any death.to the regression models.Comparison of CAS-CEA outcomes in the coverage
era. To compare actual outcomes among CAS and CEA
patients, we performed an additional propensity score
match of CAS to CEA patients in the coverage era. The
model predicting CAS receipt included age, race, gender,
prior stroke/transient ischemic attack, presence of bilateral
carotid disease, congestive heart failure, coronary artery
disease, noncarotid peripheral vascular disease, valvular
heart disease, hypertension, chronic pulmonary disease,
diabetes, and renal disease. Overlap of propensity scores
between the two cohorts was 87% (Fig 4), indicating only
modest observable differences between patient popula-
tions. Unsurprisingly, CAS recipients had much higher
adjusted 90-day (2.7% vs 1.5%; P  .001) and 270-day
(6.5% vs 4.2%; P  .001) mortality, and higher adjusted
rates of combined outcomes at 90 days (5.7% vs 4.0%; P 
.001) and 270 days (10.6% vs 7.6%; P  .001).
DISCUSSION
In a matched analysis of patients receiving carotid re-
vascularization before CAS vs subsequent to widespread
CAS coverage, we observed higher mortality and adverse
Fig 4. Distribution of the propensity scores for all Medicare
beneficiaries receiving carotid endarterectomy (gray bars) or ca-
rotid stents (black bars) during the carotid arterial stent (CAS)
coverage era (August 1, 2005 - March 31, 2006). The propensity
score was calculated from a logistic regression model predicting
CAS receipt that included multiple demographic, clinical, and
hospital-level covariates. The x-axis indicates the propensity score,
expressed in units of logit (probability)  log (probability/[1-
probability]). The y-axis indicates the percentage of observations in
each propensity score interval.clinical outcomes during the coverage era. Across localities,
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rates of adverse clinical outcomes. While some differences
were not statistically significant at the .05 level, the magni-
tude and direction of the differences remained consistent
even after multivariable statistical adjustment.
Carotid stent systems with embolic protection extend
the clinical population that may benefit from revasculariza-
tion due to the lower periprocedural risk of catheter-based
therapy compared to surgery. Nevertheless, were carotid
stents to have worse downstream clinical outcomes than
endarterectomy, their up-front clinical benefit could be
nullified, making stents a suboptimal therapeutic choice.
Among several potential explanations for our findings is
the possibility that CAS patients had modestly worse
outcomes than comparable CEA patients. While it is also
possible that carotid stents were used in the coverage era
among patients who would not have undergone carotid
endarterectomy in the pre-coverage era, we observed no
change in the overall volume of carotid revascularization
procedures between the pre-coverage and coverage eras,
rather than the increase in total procedures that would
have been expected had CAS been predominantly used in
patients who previously would not have been surgical
candidates. Our propensity score match on multiple
potential confounders further reduced the possibility
that selection of higher risk patients during the coverage
era explained the observed results.
Medicare covered CAS under a more restrictive cover-
age policy than carotid endarterectomy. Only 635 hospitals
used CAS among Medicare beneficiaries during the cover-
age era compared to over 2000 hospitals that performed
CEA. Medicare’s qualification criteria for CAS hospitals
may have improved outcomes among patients receiving
CAS by essentially requiring CAS patients to obtain care at
high-volume centers with extensive procedural experience.
Nevertheless, our results suggest that this systematic advan-
tage in the provision of CAS care did not result in compa-
rable CAS-CEA outcomes.
Comparison of primary results with direct CEA-
CAS comparison. The results of our difference-in-
difference models, matching patients across eras, suggest
more modest difference in CEA/CAS outcomes than in
our direct comparison of CEA to CAS patients in the
coverage era. The larger differences observed in the direct
comparison likely resulted from patients being selected for
CAS during the coverage era who had unobservable risk
factors. The benefit of our primary analytic approach, in
which we investigated changes in outcomes among the
combined group of CAS/CEA recipients across eras, is that
the undesirable biases of both therapy selection (so-called
“confounding by indication”), and time-invariant, unob-
served confounders (eg, the proportion of the CAS/CEA
population who smoked) were greatly diminished.
Comparisons with prior studies. While the results of
this observational study are not directly comparable to
clinical trials, it is notable that prior studies comparing CAS
to CEA have yielded varying results. The Stent-Protected
Angioplasty vs Carotid Endarterectomy (SPACE) trialdemonstrated no difference in 30-day rates of stroke and
death among patients who received CAS vs CEA (6.9% vs
6.4%). At 2 years, the rate of ipsilateral stroke combined
with any periprocedural stroke or death was 9.5% for CAS
and 8.8% for CEA (P .62).9 These results were similar to
those of the Stenting and Angioplasty with Protection in
Patients at High Risk for Endarterectomy (SAPPHIRE)
trial, in which there were no significant differences in
periprocedural stroke or death plus ipsilateral stroke or
neurological death at 1 year (5.5% CAS vs 8.4% CEA; P 
.36).6 Similarly, the CArotid Revascularization using End-
arterectomy or Stenting Systems (CARESS) trial demon-
strated no significant difference in combined death, stroke,
or AMI at 30 days (3.6% CEA vs 2.1% CAS; P  .41) or at
1 year (13.6% CEA vs 10.0% CAS; P  .30).7 Conversely,
the Endarterectomy vs Angioplasty in patients with Severe
Symptomatic Carotid Stenosis (EVA-3S) trial was stopped
early because of excess 30-day incidence of stroke or death
among CAS compared to endarterectomy patients (9.6%
CAS vs 3.9% CEA; P  .01).8 As such, the comparative
effectiveness of CAS compared to CEA remains controver-
sial, and few studies have used nonexperimental data to
compare outcomes.
Contributions of this study. The current study con-
tributes to the CAS-CEA comparative effectiveness evi-
dence base by reporting outcomes among a nationwide
cohort of patients who received CAS or CEA under non-
experimental conditions. Results of clinical trials may not
be generalizable to patient populations that differ in impor-
tant aspects from trial populations. In particular, the Medi-
care patients we studied were older (average age 76) than
patients in the SAPPHIRE trial (average age  72.5), the
EVA-3S trial (average age  70), or the SPACE trial
(average age 68). Furthermore, our study is more repre-
sentative of care outside of major academic hospitals—
patients in our study received care in over 2000 different
U.S. hospitals, while the SAPPHIRE trial (for example) was
conducted at 29 major academic centers.
A particular strength of this study is the use of the
geographic variability in the adoption of CAS to partially
replicate the effect of randomization in a clinical trial. We
assumed that a locality’s tendency to useCASmore frequently
as a therapeutic option for carotid revascularization was not
correlated with time-varying clinical characteristics of popula-
tions eligible for carotid revascularization, or in time-varying
health system characteristics. Our difference-in-difference
analysis adjusted for the residual time-invariant differences in
clinical populations and health system characteristics, as did
our use of propensity score matching.
Several of our outcome comparisons resulted in differ-
ences with two-sided P values between .05 - .10. While
such results have typically been classified in binary fashion
as statistically insignificant,22 the consistency of the find-
ings and the occurrence of some results with P values .05
suggest that chance alone is unlikely to explain our results.
Limitations. We were unable to include patients with
moderate or severe carotid disease who received medical
therapy alone. It is possible that there was a decline in the
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where CAS was rapidly adopted, thus potentially biasing
our analyses due to unobserved changes over time in the
procedure recipient population.More generally, changes in
either carotid procedure populations or health care systems
between the pre-coverage and coverage eras may have
biased our results if these changes were more common in
high-CAS-adopting localities, and if the changes were not
“captured” by matching patients across treatment eras
within localities.
Our study was also limited by relatively low use of CAS
relative to endarterectomy even in areas that were robust
adopters of CAS. Even in the top decile of HRRs for CAS
adoption, the overall rate of CAS use during the coverage
era was only 27%. It is possible that modest differences in
clinical outcomes for CAS compared to CEA would not
have been detected, since outcomes would have differed for
only a fraction of patients receiving carotid revasculariza-
tion across eras. Furthermore, the rates of adverse out-
comes in this study were uniformly lower for both CEA and
CAS recipients compared to clinical trial enrollees. Al-
though this could have been caused by under-recording of
clinical outcomes in the Medicare database, it is also possi-
ble that the cohort of patients we examined had, on aver-
age, less severe carotid arterial disease (eg, asymptomatic
stenoses) than clinical trial enrollees for whom rigorous
inclusion criteria were necessarily applied.
There may have been undercoding or miscoding of
CAS during the pre-coverage era, however CAS with cere-
bral protection was only FDA-approved for marketing in
the last month of the pre-coverage era. It is likely, therefore,
that the vast majority of CAS use in the pre-coverage area
was in the context of clinical trials, and CMS did reimburse
CAS used in clinical trials throughout the pre-coverage era.
It is also possible that CAS in the pre-coverage era was
conducted without cerebral protection, however, this
should have resulted in improved outcomes during the
coverage era in high-adopting localities due to providers
switching to cerebral protection CAS; instead we observed
worsened outcomes.
Finally, our results could have been caused by provider
inexperience with CAS relative to CEA, although this pos-
sibility was lessened somewhat by the terms of Medicare
CAS coverage, which required hospitals to certify either
prior participation in CAS clinical trials or the establish-
ment of CAS clinical programs with multiple required
quality components (eg, advanced radiologic services, in-
terventionalist certification, etc). Changes over time in the
type of specialists performing carotid interventions may
likewise have resulted in different clinical outcomes during
the coverage era, although we had no method of determin-
ing the specialty of CAS interventionalists.
Summary. In this observational study of Medicare
beneficiaries undergoing carotid revascularization, we de-
tected increases in mortality and in the combined rates of
AMI, death, and stroke in areas where carotid stenting was
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